Structural Heart

This structural heart channel includes news, videos, podcasts and other content related to diagnosis and treatment of structural heart disease. Topics covered include heart valve repair and replacement, transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), left atrial appendage (LAA) occlusion, heart failure interventional device therapies, and closing holes in the heart using, including occlusion of atrial septal defects (ASDs), ventricular septal defects (VSDs) and patent foramen ovales (PFOs).

Repair of Tricuspid Valve Leak CTCR-MVS - Evaluating the Benefit of Concomitant Tricuspid Repair During Mitral Valve Surgery.

News | Structural Heart

Repair of Tricuspid Valve Leak During Mitral Valve Surgery May Benefit Some Adults

November 18, 2021 — Adults undergoing mitral valve surgery who have less than severe leakage of the tricuspid valve may ...

November 18, 2021

News | Structural Heart

Surgery to Replace Heart Valve Beneficial Even With No Symptoms of Severe Aortic Stenosis

November 17, 2021 — For people experiencing severe aortic stenosis who do not have symptoms or need symptom relief ...

November 17, 2021

Medtronic Apollo Intrepid TMVR is currently in the middle of a U.S. clinical trial. #TCT #TCT21 #TMVR

News | Structural Heart

Medtronic Intrepid Transcatheter Mitral Valve Successfully Uses Transfemoral Delivery

November 10, 2021 — Medtronic presented early data for its self-expanding Intrepid transcatheter mitral valve ...

November 10, 2021

News | Heart Failure

Ancora Heart AccuCinch System Shows Positive 12 Month Outcomes in Multi-study Analysis

November 10, 2021 — Ancora Heart Inc., a company developing a novel therapy to address heart failure, announced results ...

November 10, 2021

TCT 2021 Announces Late-Breaking Clinical Trials

Feature | TCT

Links to all the TCT 2021 Late-Breaking Clinical Trials

November 10, 2021 — There were nine late-breaking trials and 13 late-breaking science presentations at the 2021 Transcat ...

November 10, 2021

The Teleflex Manta large bore vascular closure device #TCT2021

News | Vascular Closure Devices

Plug-based Vascular Closure Following TAVR Offers Shorter Hemostasis Time Than Suture-based Devices

November 9, 2021 — Results from the largest randomized trial available comparing different closure device strategies ...

November 09, 2021

TAVR CT image reconstruction of an implanted Medtronic CoreValve. #TCT21 #TCT #TAVR #SURTAVI

News | Heart Valve Technology

Intermediate-risk Patients Have Similar Five-year Outcomes With Transcatheter or Surgical Aortic Valve Replacement

November 9, 2021 — New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality ...

November 09, 2021

A PARTNER 3 trial economic analysis shows for low surgical risk patients, TAVR is cost-saving compared with SAVR. TAVR Sapien Valve visualized using a GE guidance software. #TCT2021

News | Structural Heart

TAVR Is Cost Effective Compared With Surgical Replacement for Low-risk Patients

November 9, 2021 — An economic analysis of data from PARTNER 3, a randomized trial comparing transcatheter aortic valve ...

November 09, 2021

The two FDA-cleared transcatheter LAA occlusion devices on the U.S. market were compared in the SWISS-APERO and SEAL FLX trials presented at TCT 2021. Left is the Abbott Amulet device, right is the newest generation Watchman FLX device.

News | Left Atrial Appendage (LAA) Occluders

First Comparison of Amulet and Watchman FLX LAA Closure Devices Found Similar Outcomes

November 8, 2021 – SWISS-APERO is the first randomized clinical trial comparing the Abbott Amulet left atrial appendage ...

November 08, 2021

The Edwards Lifesciences Evoque transcatheter tricuspid valve replacement system demonstrated sustained favorable patient outcomes at six months in the TRISCEND study.

News | Structural Heart

Six-Month Outcomes Positive for Transfemoral Tricuspid Valve in Tricuspid Regurgitation Patients

November 8, 2021 — Results from a clinical trial of the Edwards Lifesciences Evoque transcatheter tricuspid valve ...

November 08, 2021

The FDA cleared the world's first photon-counting computed tomography (CT) scanner, the Siemens Naeotom Alpha, in late September. This new technology will likely change the future direction of CT. Biosense Webster also announced the first cases using its Heliostar radiofrequency balloon ablation catheter were completed in September. Both were among the top stories in October.

Feature | By Dave Fornell, DAIC Editor

November 1, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

November 01, 2021

Videos | Structural Heart

VIDEO: Abbott Structural Heart CMO Shares Views on Future of Valve Interventions

Dr. Neil Moat, MBBS, chief medical officer of Abbott's structural heart business, was a cardiac surgeon specializing in ...

October 15, 2021

$Cardiac CTA derived left atrium emptying fraction (LAEF) improves predictive performance of established clinical risk scores and may be used to assess TAVR patient risk during pre-procedure workup and post-procedural surveillance. These images show LAVmax (A and B), LAVmin (C and D), and LAEF using cardiac CTA. LAEF was calculated as (LAVmax-LAVmin)/LAVmax x 100. Given LAVmax of 109 mL and LAVmin of 80 mL, the LAEF was calculated to be 27%. Image courtesy of AJR.$